---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-028111"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2026-08-17T12:00:30+00:00"
generated_at: "2026-08-17T12:06:03.757171+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NRx Q2 2026: net loss $18M, cash $26.7M; FDA ketamine ANDA only needs attestation

## Summary
- FDA review of ANDA for preservative-free ketamine found no drug-related major deficiencies; only manufacturer's attestation submitted, aiming for 2026 approval.
- Closed underwritten public offering for gross proceeds of $22.3M; cash at June 30, 2026 was $26.7M vs $7.8M at Dec 31, 2025.
- Selected by DARPA as prime contractor for SPARC-TMS trial of NRX-101 with robotic TMS; non-dilutive funding >$11.5M.
- Appointed Glenn Tyson as first Chief Commercial Officer; initiated commercial scale manufacturing of 5M ketamine doses.
- Net loss for six months ended June 30, 2026 was $18.0M vs $23.1M in 2025; net operating loss $11.3M vs $7.6M.

## SEC filing metadata
- accession: 0001437749-26-028111
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2026-08-17T12:00:30+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774926028111/0001437749-26-028111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774926028111/nrxp20260817_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-028111
- JSON: https://secwatch.observer/filing/0001437749-26-028111.json
- Plain text: https://secwatch.observer/filing/0001437749-26-028111.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.